

2025-01-29

The self-archived postprint version of this journal article is available at Linköping University Institutional Repository (DiVA):

<https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-210690>

# **Dabigatran Attenuates the Binding of Thrombin to Platelets-A Novel Mechanism of Action**

Tomas Lindahl, Aishwarya Prasanna Kumar, Teresia Hallstroem, Ahmed Al-Hashimi, Anna Du Rietz, Elena Arlaman, Kajsa Uvdal and Ankit Macwan

*Thrombosis and Haemostasis*, (2024)

Publisher: Thieme Gruppe

<https://doi.org/10.1055/a-2483-0107>

N.B.: When citing this work, cite the original publication.

Copyright holder: See original publication

# Dabigatran attenuates the binding of thrombin to platelets - a novel mechanism of action

Tomas L. Lindahl<sup>1\*#</sup>, Aishwarya Prasanna Kumar<sup>1\*</sup>, Teresia Hallström<sup>2</sup>, Ahmed Al-Hashimi<sup>1</sup>, Anna du Rietz<sup>3</sup>, Elena Arlaman<sup>1</sup>, Kajsa Uvdal<sup>3</sup> and Ankit S. Macwan<sup>1</sup>.

1) Division of Clinical Chemistry and Pharmacology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

2) NanoTemper Technologies, Munich, Germany

3) Division of Molecular Surface Physics and Nanoscience, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden

\* Contributed equally

**#Corresponding author:** Tomas L. Lindahl, [tomas.lindahl@liu.se](mailto:tomas.lindahl@liu.se)

Department of Biomedical and Clinical Sciences, Linköping University, Linköping University Hospital, Building 420, level 11, SE-581 85 Linköping, Sweden.

**Key words:** Thrombin, dabigatran, microscale thermophoresis, platelets

**Short title:** Dabigatran inhibits thrombin binding to platelets.

## **Abstract**

Thrombin is a multifunctional regulatory enzyme of the hemostasis and has both pro- and anticoagulant roles. It has, therefore, been a main target for drug discovery over many decades. Thrombin is a serine protease and possesses two positively charged regions called exosites, through which it is known to bind to many substrates. Dabigatran is a thrombin inhibitor and is widely used as an oral anticoagulant for the antithrombotic treatment of atrial fibrillation and venous thromboembolism. The mechanism by which dabigatran inhibits thrombin is the blockage of the active site, however, its effect on thrombin binding to its substrates has not been studied thoroughly and is thus poorly understood. We have discovered that apart from blocking the active site, dabigatran also inhibits thrombin binding to platelets, which is an important step in the hemostasis. This was achieved by evaluating the binding of fluorescently labelled thrombin to platelets by flow cytometry. Further, to confirm the results we utilized modern techniques for biomolecular binding studies, microscale thermophoresis combined with SPR, which validated the results. The inhibition of thrombin binding to its substrates in flow cytometry was dose dependent with IC<sub>50</sub> of 118 nM which was slightly lower than for inhibition of platelet activation and is close to the clinically relevant plasma concentration of dabigatran. Since thrombin has numerous functions beyond the cardiovascular system, this finding may have important implications.

## **1.0 Introduction**

Thrombin is not only the prima ballerina in the coagulation cascade but also a strong platelet activator binding to the protease activated receptors (PARs) 1 and 4 [1]. The catalytic activity and specificity of thrombin is highly dependent on two intramolecular recognition sites located distant from the active site. These domains, designated fibrinogen recognition site and heparin binding site, or exosite I and II, respectively, facilitate proteolysis by interacting with anionic surfaces on various substrates (Fig. 1). Exosite II binds to heparin [2], factors V and VIII [3], PAR4 [4] and may also bind to glycoprotein Ib (GPIb) [4] on platelets. Exosite I is the binding epitope for bivalirudin, fibrinogen, thrombomodulin, hirudin, and PAR1 and contributes to binding to GPIb [5]. The exosites I and II on thrombin may be blocked by the DNA-oligomers HD1 and HD22 [6], respectively. The binding of thrombin exosite I to PAR1 is mediated by a

hirudin-like sequence immediately downstream of the tethered ligand domain in PAR1 [7]. This sequence does not exist on PAR4. Instead, thrombin has been reported to have low affinity for the thrombin cleavage site of PAR4 [8].

Binding of thrombin to GPIIb via exosite II facilitates the binding to PAR1 [4, 9], whereas exosite I binds directly to the hirudin-like domain of PAR1 [10]. Thrombin's strong affinity for PAR1 allows transient PAR1 signalling sufficient to elicit significant  $\alpha$ -granule release and platelet aggregation in presence of therapeutic heparin concentration at physiological antithrombin levels. In contrast, inhibition of thrombin-induced PAR4-mediated platelet activation was complete and sustained [11].

Oral anticoagulants are used world-wide to prevent thrombosis, for example in patients with atrial fibrillation, venous thrombosis, and prosthetic heart valves. In recent years oral reversible direct thrombin and factor Xa inhibitors have substituted vitamin K antagonists to large extent for most indications, with the exceptions of prosthetic heart valves and patients with thromboembolism and being triple positive for lupus anticoagulant. The first drug of this class in clinical use at present, approved 2010, was dabigatran etexilate from Boehringer-Ingelheim which is a prodrug metabolised to its active form dabigatran by endogenous esterases [12, 13]. Dabigatran is a direct, reversible thrombin inhibitor with half-maximal inhibitory concentration (IC<sub>50</sub>) of 9.3 nmol/L [14], K<sub>i</sub> 4.5 nmol/L [15]. Dabigatran inhibits both free and fibrin-bound thrombin and has no effect on thrombin binding to a glycoprotein Iba peptide [16]. In this study we report that along with blocking the active site, dabigatran also inhibits binding of thrombin to platelets.

## **2.0 Materials and Methods**

### **2.1 Reagents and antibodies**

(H-D-Phe-Pro-Arg-chloromethylketone (PPACK) dihydrochloride, apyrase, PGI<sub>2</sub>, 14-azido-3,6,9,12-tetraoxatetradecan-1-amine and disposable PD 10 desalting columns were from Merck, Darmstadt, Germany. Human  $\alpha$ -thrombin was purchased from Haematologic Technologies, Vermont, USA. The DNA-aptamers HD1, HD22 and dibenzocyclooctyne (DBCO) functionalized clickable aptamers were from Biomers.net (Ulm, Germany). Dabigatran was purchased from Selleckchem (Munich, Germany).

Argatroban (Novastan) was purchased from FrostPharma, Danderyd, Sweden. Melagatran was purchased from MedChemTronica, Sollentuna, Sweden. Blood collection tubes were from Greiner Bio-One GmbH, Frickenhausen, Germany. Amine coupling kit, HBS-EP buffer and acetate buffer were from Cytiva Europe GmbH, Uppsala, Sweden. Antibodies, anti-CD62P (P-selectin)-phycoerythrin (PE) or allophycocyanin (APC) with corresponding isotype antibodies were from BD Biosciences, thrombin monoclonal antibody (MA1-43019) and Alexa Fluor™ 555 Antibody labelling kit was from Life Technologies Europe BV, and fluorescein isothiocyanate (FITC)-conjugated chicken antibodies directed towards human fibrinogen was provided by Diapensia AB (Linköping, Sweden, [www.diapensia.se](http://www.diapensia.se)). Protein Labeling Kit RED-NHS 2nd Generation and Monolith Premium Capillaries were from NanoTemper Technologies, Munich, Germany.

## **2.2 Blood collection and sample preparation**

Blood from healthy human volunteers was collected, after informed consent, in Vacuette®, 9 ml ACD-A tubes to prepare platelets rich plasma (PRP) and washed as reported previously [17]. Briefly, blood was centrifuged at 150xg for 15 min at RT to get PRP and then again at 480xg after addition of 1U/ml apyrase and 100nM PGI<sub>2</sub> to pellet the platelets. The plasma phase was carefully replaced by Krebs Ringer Glucose (KRG; 20 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO<sub>4</sub>, 1.7 mM KH<sub>2</sub>PO<sub>4</sub>, 8.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 10 mM glucose, pH 7.3) buffer supplemented with apyrase and PGI<sub>2</sub> and platelet count was adjusted after recalcification. The platelet samples were incubated for 30 min at RT after isolation before usage in any experiments. The collection of blood samples from healthy donors was approved by the local ethics committee in Linköping, Sweden, decision No 2012/382–31.

## **2.3 Chromogenic thrombin substrate assay**

Thrombin activity was measured using the Chromogenix S-2238™ substrate (DiaPharma, West Chester, USA), according to the manufacturer's instructions using Enspire multimode plate reader (Perkin Elmer, Sollentuna, Sweden) to evaluate and compare the effect of labelling of thrombin and the treatment of PPACK (H-D-Phe-Pro-Arg-chloromethylketone; covalent inhibitor of active site). Thrombin was labelled using protein labelling Kit RED-NHS 2nd generation according to the manufacturer's instructions. For PPACK treatment, thrombin was first incubated with double molar

concentration of PPACK dihydrochloride for 30 mins and unbound PPACK was removed using PD10 chromatography column. Briefly, unlabelled, labelled and PPACK thrombin were diluted in 50µl buffer (50mM Tris, with 0.2% BSA pH 8.3) and incubated at 37°C for 4 min. The reaction was started by mixing 50µl of S-2238 substrate and incubated at 37°C for 3 min. The final concentration of thrombin and PPACK in the reaction mixture was 0.16 µM. The reaction was stopped with the addition of 25 µL of 20% acetic acid, and the absorbance was measured at 405nm. The data was calculated using One-way ANOVA followed by Bartlett's test using GraphPad Prism version 10.0.2 for Windows, GraphPad Software, Boston, Massachusetts USA, [www.graphpad.com](http://www.graphpad.com).

## 2.4 Flow cytometry

Binding of thrombin to platelets was analyzed by flow cytometry using washed platelets ( $300 \times 10^9/L$ ). RED-NHS labeled thrombin (0.5 µM) was used to determine the binding of thrombin to platelets in the presence or absence of various inhibitors. To study the contribution of the thrombin exosites, DNA aptamers HD1 (exosite 1 inhibitor) or HD22 (exosite 2 inhibitor) was used at 1µM concentration as previously reported [18]. To study the role and contribution of the thrombin active site, four different active site inhibitors dabigatran (318 nM), argatroban (318 nM), melagatran (1µM) or PPACK was used. For experiments with PPACK, it was prepared as described in above section and 0.5 µM PPACK thrombin labelled with NHS RED 2<sup>nd</sup> generation was compared with NHS RED 2<sup>nd</sup> generation labelled thrombin. HD1 and HD22 (1 µM) was also used with PPACK thrombin. Platelet activation was assessed by using anti-human-CD62P (P-selectin, PE or APC labelled and 1.25 µg/mL), and FITC-conjugated anti human fibrinogen chicken antibody (1 µg/mL). Corresponding isotype antibodies were used as a control. Briefly, washed platelets were incubated with various combinations of thrombin, antibodies, and inhibitors in HEPES buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl<sub>2</sub>, 5.6 mM glucose, 1 mg/mL bovine serum albumin and 20 mM HEPES, pH 7.40) and dimethyl sulfoxide (DMSO) (final concentration 0.5% v/v) in the dark at RT for 10 mins. Samples were then diluted 1:10 with HEPES buffer and analyzed by flow cytometry on a Gallios™ flow cytometer (Beckman Coulter Inc., Fullerton, CA, USA). The median fluorescence intensity (MFI) was used for analysis. MFI of thrombin without any inhibitors was set to 100% and other results were normalized against it and presented as relative fluorescence intensity (RFI). These experiments were also

performed with unlabeled thrombin using or Alexa Fluor™ 555 labeled thrombin monoclonal antibody which resulted in similar outcome. The data was calculated using One-way ANOVA followed by Brown-Forsythe test using GraphPad Prism. For IC50 analysis, washed platelets were “spiked” with dabigatran to the following final concentrations 2-600 nM and 0.5 % (v/v) DMSO in all samples in HEPES and analyzed as described above. The logarithm of the dabigatran concentration was plotted against the response (expressed in MFI) and the IC50 values were calculated using the GraphPad Prisms built-in equation "Dose-Response - Inhibition" and "log(inhibitor) vs. response - Variable slope (four parameters)". The curves are fit using nonlinear regression with the drug concentrations transformed to a logarithmic scale.

## 2.5 Microscale thermophoresis

Microscale thermophoresis (MST) was used to analyze the interaction of thrombin with platelets. Thrombin was labeled using NHS-Red 2<sup>nd</sup> generation and the concentration of thrombin to be used was determined by the degree of fluorescence using pretest analysis of the Monolith NT.115 i software (NanoTemper) and, the average concentration used was 55 nM. The platelet concentration used was  $\sim 1800 \times 10^9$  /mL and 1276 PAR1 [19], 539 PAR4 [20] and 25,000 GP1b [21] receptors per platelet were used for the calculations of receptor concentration. Thus, the highest ligand concentration of platelets in the MST experiment was 80nM which was diluted 16 times serially and evaluated for binding to constant thrombin concentration to get the binding curve. Briefly, washed human platelets (highest concentration  $1800 \times 10^9$  /mL) were diluted serially 16 times using PBS+0.005% NP40 buffer, pH 7.4 and mixed with equal amount (v/v) of RED NHS labelled thrombin (55 nM) diluted in the same buffer in the presence or absence of various inhibitors like HD1 (1 $\mu$ M), HD22 (1 $\mu$ M), dabigatran (318 nM) or argatroban (318 nM) and transferred to the Monolith Premium Capillaries. The capillaries were placed in the Monolith instrument and thermophoresis was measured at room temperature with medium MST power and 80% LED intensity. The data was analyzed using Monolith NT.115 i software. PPACK thrombin was used instead of regular thrombin for the experiments of PPACK. To investigate the effect of dabigatran (318 nM) on thrombin exosites, binding of DNA aptamers HD1 (highest concentration 1 $\mu$ M) or HD22 (highest concentration 1 $\mu$ M) or heparin (highest concentration 1 U/ml) to thrombin in a buffer without platelets was evaluated. As

described above the ligand (HD1/HD22/Heparin) was diluted 16 times serially and mixed with equal amount (v/v) of RED NHS labelled thrombin (55 nM) in the presence or absence of dabigatran 318 nM or 3180 nM and binding was evaluated using MST. Data analyses were performed using the MO. Affinity Analysis software (NanoTemper) and normalized display of fraction bound vs ligand concentration, or  $\Delta F_{\text{norm}}$  (%) vs ligand concentration were used. For plots with fraction bound,  $\Delta F_{\text{norm}}$  values of the curve are divided by curve amplitude resulting in range of values between 0 and 1. To compute change in normalized fluorescence  $\Delta F_{\text{norm}}$  (%) the baseline  $F_{\text{norm}}$  values is subtracted from all data points. For the statistical calculations shown in Fig. 3, the binding curves from the MST experiments are fitted using the one phase decay equation in the exponential model using GraphPad Prism.

## 2.6 Surface plasmon resonance

Surface plasmon resonance (SPR) was used to evaluate the effect of dabigatran on the binding of thrombin to DNA aptamers HD1 and HD22 using a Biacore 3000 system. HD1 and HD22 were immobilized in multiple steps in separate channels on a CM5 sensor chip (Biacore, Uppsala, Sweden). Briefly, 75  $\mu\text{l}$  1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimid (NHS) were injected at a flowrate of 5  $\mu\text{l}/\text{min}$ , then 90  $\mu\text{l}$  10 mM 14-azido-3,6,9,12-tetraoxatetradecan-1-amine in pH 11 potassium dihydrogen phosphate/NaOH buffer was injected at a flowrate of 1  $\mu\text{l}/\text{min}$ . This was followed by an injection of 60  $\mu\text{l}$  ethanol amine at 10  $\mu\text{l}/\text{min}$ . Finally, 90  $\mu\text{l}$  DBCO functionalized aptamer at a concentration of 42  $\mu\text{g}/\text{ml}$  in pH 4 acetate buffer was injected at 1  $\mu\text{l}/\text{min}$ . The DBCO moiety on the aptamer will bind to the azide via click chemistry. Thrombin was used at 100 nM as maximum response was obtained at this concentration. It was mixed with three molar equivalents of dabigatran dissolved in DMSO or the corresponding volume of DMSO and injections of 30  $\mu\text{l}$  were performed at 10  $\mu\text{l}/\text{min}$ , repeated three times. The data was analyzed using MATLAB (R2023b). The data was filtered for noise using the smooth function with a 5-point moving average over areas where the needle movement of the Biacore induced additional noise. Spike artefacts induced by the large jump in refractive index upon start and finish of injection were removed using the Hampel function. Baseline correction was done using a straight line and an asymmetric truncated quadratic function using script by Mazet [22]. The used MATLAB scripts and raw data are available upon request.

### 3.0 Results

#### 3.1 Binding of thrombin to platelets and effect of inhibitors

The binding of thrombin to platelets was determined using fluorescently labelled thrombin (0.5  $\mu\text{M}$ ) and washed platelets, measured by flow cytometry. The labeling of thrombin had no significant effect on the enzymatic activity as confirmed by the chromogenic substrate assay. Thus, compared to unlabeled thrombin (0.16  $\mu\text{M}$ ), NHS RED labeled thrombin (0.16  $\mu\text{M}$ ) retained 94% activity whereas PPACK treated thrombin (0.16  $\mu\text{M}$ ) showed 0.5% activity (Fig. S1). When considering total thrombin binding to platelets in the absence of any inhibitors as 100%, HD1 (1  $\mu\text{M}$ ) and HD22 (1  $\mu\text{M}$ ) inhibited thrombin binding to platelets by 43 and 32%, respectively (Fig. 2). The combination of both aptamers inhibited binding completely, as expected. In these experiments' dabigatran (318 nM), a thrombin active site inhibitor, was used as a positive control that inhibits enzymatic activity. Surprisingly, along with inhibiting the enzymatic activity, dabigatran also blocked thrombin binding to the platelets. To confirm the efficacy of the inhibitors and the viability or reactivity of the platelets used for the experiments, platelet activation/function markers like p-selectin exposure and fibrinogen binding to platelet were also measured, which showed similar trends, complementing the thrombin binding results (Fig. 2). The result on binding indicated that the blockage of the active site also blocks the binding of thrombin exosites I and II. Thus, the active site, along with the exosites, play an important role in binding thrombin to platelets. To confirm this hypothesis, we used argatroban (318 nM) and melagatran (1  $\mu\text{M}$ ), inhibitors similar in size, nature and function to thrombin which showed similar characteristics i.e., inhibition of thrombin binding to platelets along with blocking the active site (Fig. 2 & S2). PPACK (H-D-Phe-Pro-Arg-chloromethylketone), another active site inhibitor also blocked thrombin binding to platelets, albeit not completely like dabigatran (Fig. S3). PPACK, however, is structurally different from dabigatran and is a covalent inhibitor of the active site. To rule out any interference of fluorescence labeling on thrombin binding to platelets, the results obtained with labeled thrombin were confirmed by unlabeled thrombin and an anti-thrombin monoclonal antibody (Fig. S4) which showed a similar trend and strengthened our findings. Similarly, the effect of pre-incubation of dabigatran to thrombin was also evaluated,

which showed that dabigatran inhibited thrombin binds to the platelets irrespective of pre-incubation status (Fig. S5).

### **3.2 Binding analysis using microscale thermophoresis**

We used MST to validate the dabigatran effect on thrombin binding to platelets. Complementing the findings observed with flow cytometry, HD1 (1  $\mu\text{M}$ ) and HD22 (1  $\mu\text{M}$ ) inhibited thrombin (55nM) binding to platelets, but not completely (Fig. 3A). However, dabigatran (318 nM) showed complete inhibition of binding using MST (Fig. 3B). To further confirm the effect of blockage of active site on overall binding, we used argatroban (318 nM) as well as the covalent inhibitor of active site, PPACK (55nM), both of which inhibited binding of thrombin to the platelets.

### **3.3 Effect of dabigatran on thrombin exosites**

To further investigate the mechanism by which dabigatran block thrombin binding to platelets, we assessed the effect of dabigatran binding to thrombin active site on the binding of HD1 and HD22 to the exosites. This was achieved by evaluating the binding of thrombin to HD1 and HD22 in the presence and absence of dabigatran in a pure system without platelets using two biophysical methods, microscale thermophoresis [23, 24] and surface plasmon resonance [25].

MST did not show any effect of the presence or absence of the dabigatran (318 nM) on thrombin binding to HD1 (1  $\mu\text{M}$ ; Fig. 4A) or HD22 (1  $\mu\text{M}$ ; Fig. 4B) or heparin (1U/ml) (Fig. 4C). Additionally, increasing the concentration of the dabigatran ten times (3180 nM) also had no effect on exosite ligands binding (Fig. S6).

SPR also did not indicate any effect of dabigatran binding to thrombin on the interaction with either HD1 (Fig. 5A) or HD22 (Fig. 5B). The shape and intensities (response signal) of the sensograms with and without dabigatran were very similar. HD22 initially showed a minor trend where the thrombin dabigatran complex might have a slightly higher affinity to HD22, however, increased injection volume (60 $\mu\text{l}$ ) showed no differences in the sensograms (Fig. 5C). The signal intensity of the SPR experiments were on a relatively low level, which is consistent with other published data on thrombin in SPR [26, 27]. To allow closer inspection of the obtained sensograms individual plots can be found in Fig. S7.

### **3.4 Dabigatran mediated inhibition of binding is dose dependent**

To find out whether the dabigatran effect on thrombin binding is dose dependent or not, IC<sub>50</sub> analysis was carried out. Dabigatran concentrations from 4-600 nM were used for these experiments and their effect on thrombin binding and its functional activity indicators p-selectin exposure and fibrinogen binding was evaluated using flow cytometry and fluorescently labeled thrombin and the respective antibodies. We found the effect of dabigatran to be dose dependent and that the IC<sub>50</sub> for inhibition of binding was 118 nM. The IC<sub>50</sub> for inhibition of p-selectin exposure and fibrinogen binding was 126 and 185 nM, respectively (Fig. 6).

## **4.0 Discussion**

In this study we have shown that the thrombin active site inhibitor dabigatran effectively inhibits thrombin binding to all platelet thrombin receptors. The binding was analysed using flow cytometry and further characterized by microscale thermophoresis and surface plasmon resonance.

Most studies analyzing affinity or binding of thrombin to platelets used radiolabeled thrombin and were performed more than 30 years ago, at that time the platelet thrombin receptors PAR1 and 4 were not yet identified [28, 29]. Although the use of radiolabeled proteins to analyze the interaction between two biomolecules has been a classic way, is not practical due to obvious health hazards and strict regulations. Thus, to confirm our findings, we used two modern biophysical techniques specialized on the measurement of interactions between biomolecules, MST and SPR. Both techniques are safe and have been successfully applied to measure the affinity between biomolecules. MST can analyze biomolecular interactions in an immobilization-free system where one of the binding partners is fluorescently labeled and its motion in a micro temperature gradient is measured. This technique is particularly useful for this study as live platelets can be used as one of the partners to analyze the binding characteristics. On the other hand, SPR is a standard and valuable method specialized in analyzing interactions between molecules with respect to both affinity and kinetics [30, 31].

It is a possibility that the labelling of thrombin with a fluorescent dye might affect its ability to bind or function properly, however, labelled thrombin's unaffected ability to cleave S-2238 chromogenic substrate (Fig. S1), eliciting P-selectin exposure, fibrinogen binding and similar results obtained when using anti-thrombin antibody (Fig. S4) rule out this suspicion. Further, dabigatran quenching the fluorescence signal or affecting exosite affinity can also be excluded by unaffected binding of exosite ligands to the thrombin in the presence of dabigatran which is demonstrated with both MST and SPR (Fig. 4 & 5). Although, PPACK is a potent inhibitor of the active site, it showed only 50% reduction in the binding when evaluated by flow cytometry (Fig. S3), which has also been observed before [32]. Further, the remaining ~50% binding was not only due to the exosites, as blockage of the exosites by aptamers could not abolish the binding to platelets completely (Fig. S3). However, when analysed by MST, no binding could be detected to platelets which points towards the differences in techniques but strengthened the finding of this study as dabigatran showed inhibition irrespectively. The inhibition of thrombin by dabigatran has been shown to be the active site blockage with a reported  $K_d$  of 10 nM [15] for thrombin-induced aggregation of gel-filtered platelets, however, to the best of our knowledge, the effect of dabigatran on binding of thrombin exosites has not been reported. The  $IC_{50}$  values were obtained using flow cytometry and washed platelets.  $IC_{50}$  for platelet activation markers p-selectin exposure (122 nM) and fibrinogen binding (185 nM) was much higher than the reported 10 nM [15] using aggregometry, however, the same study has reported the  $IC_{50}$  of 560nM when a thrombin generation assay was used. Similarly, another study [30] has reported the  $IC_{50}$  of 2  $\mu$ M using thrombin generation method indicating a large variation in the  $IC_{50}$  values obtained, probably dependent on the system and methodology used. However, the  $IC_{50}$  values we obtained were well within the range of reported drug concentrations in patients where the peak concentration in elderly healthy subjects was about 540 nM [13, 33].

Our results demonstrate that the small molecules dabigatran, argatroban and PPACK binding to the active site of thrombin strongly attenuate the binding of thrombin to the surface of platelets, in addition to the well-known inhibition of the enzymatic activity. Our findings are in good agreement with an earlier study where numerous important interactions between PAR1 N-terminus uncleaved fragment and thrombin active site was shown by crystallography [10] and, thus, any disturbance in these interactions can

lead to destabilization of binding. Further, thrombin active site occupancy by a ligand has been reported to decrease solvent accessibility of the regions in vicinity of the active site, induce backbone dynamics changes, and inhibit exosite interaction to its ligands [16, 34, 35]. Amongst these, the most relevant study supporting our observations has shown that dabigatran attenuates the binding of various substrates to exosite 1 or 2 of thrombin, however, surprisingly in their study argatroban enhanced the exosite binding of its substrates [16]. Contrary to these, it has been shown that dabigatran does not affect thrombin interaction with fibrinogen, which indicates that dabigatran bound catalytically inactive thrombin may still be able to interact with its substrates via exosite 1. This observation has also been reported earlier [36, 37]. However, in these studies cells other than platelets were used and the effect that they have measured i.e., PAR1 expression on cell surface after prolonged incubation or destabilization of the endothelial barrier, are not relevant in case of the platelets. We also investigated the effect of dabigatran on binding of DNA aptamers to thrombin exosites by MST and SPR which showed that in absence of platelets, dabigatran does not inhibit ligand binding to thrombin exosites. Although the shape of the interaction curve for thrombin and HD1 is not a typical curve obtained in SPR measurements it is in good agreement with results published in this field. Ye et al studied the binding of thrombin and fibrinogen [38] Wang et al [39] studied the interaction between thrombin and berberin. The resulting curves in both publications were of similar shapes as in this study. The reason for the rapid binding and releasing observed in these curves would be interesting to investigate but is outside of the scope of this study. As SPR is only measured at one thrombin concentration it is not possible to infer detailed conclusions on the possible effect on kinetics that dabigatran might exert. The shapes and intensities of the curves in both presence and absence is very similar and therefore the binding of exosites I and II is not altered to a degree where it may explain the results where dabigatran greatly decreases the binding of thrombin to platelets.

Studies using isolated systems of thrombin with its natural or synthetic substrates do not have the similar outcome when cells or platelets have been involved. Thus, our results indicate that dabigatran binding does not affect exosite structure per se to a major extent, allowing small free molecules like peptides, DNA aptamers or even larger molecules like fibrinogen to bind. Dabigatran still induces enough dynamic change to affect its binding to the complex receptor system like platelets. Structural, biochemical

and mutagenesis analysis suggests that in most cases, both exosites are involved in binding and/or catalytic functions, either directly via the substrate interaction or indirectly by facilitating the binding by interacting with the cofactor [40]. PARs are known to have a crosstalk between same or other types of receptors and show diversified interactions and functions. Dimerization is, therefore, a common phenomenon in PAR activation [41, 42]. GP1b acts as a cofactor for thrombin to bind to PARs on the platelets [43] and, similarly, PAR1 acts as a facilitator for PAR4 cleavage by thrombin [44]. The observations of various homo- or hetero-dimerization of receptors on platelet surface like PAR1/PAR1, PAR4/PAR4 [45, 46], PAR1/PAR4 [45], and PAR4/P2Y12 [47] supports the hypothesis that thrombin binding to platelets is complex, possibly requiring all three structural components together, which may explain the dabigatran effect observed in this study. One of the limitations of this study is the lack of knowledge on how dabigatran inhibited thrombin would react with ligands other than platelets under physiological conditions. The other limitation is that the exact mechanism behind inhibition elicited by dabigatran on the binding of thrombin to platelets is unclear at present. Two insertion loops near the active site cleft, known as the 60-loop and the  $\gamma$  loop (Fig. 1) have been reported to play key roles in determining the substrate and inhibitor specificity as well as catalytic activity of thrombin [48-50] and might have a role in this mechanism. However, it will have to be evaluated structurally which is beyond the scope of the current study.

The inhibition by dabigatran of thrombin binding to platelets may contribute to its antithrombotic effect. So far dabigatran is the only direct oral anticoagulant drug reported to be associated with less ischemic stroke compared to warfarin [12], although there are no randomized clinical trials comparing DOACs head-to-head. However, the dual mechanism inhibiting thrombin activation of platelets may increase bleeding risk, possibly the effect would be most important at lower concentrations of dabigatran. Interestingly, in a large Swedish registry study, patients with non-valvular atrial fibrillation on reduced dose of apixaban had lower risk for major bleeding HR 0.62 (95% CI 0.44-0.88) in comparison with patients on a reduced dose dabigatran. There was no such difference for standard doses [51].

Furthermore, thrombin is probably the most versatile and broad-spectrum enzyme in the cardiovascular milieu, and it has functions that spans from haemostasis,

coagulation, inflammation to immunity, and for all these functions its ability to bind to its substrates is a primary requirement. Thus, the inhibitory effect by dabigatran on thrombin binding to PARs may have wider implications.

## **5.0 Acknowledgements**

We are thankful to all the blood donors for the study and very grateful to Dr Dean Derbyshire of ProLinc facility, Linköping University for his valuable discussions and inputs about the structural features of thrombin and its interactions.

## **6.0 Funding**

This study was supported by grants with TL as main and AM as co-applicant from the Swedish Research Council no. 2020-01002 and the Swedish Heart-Lung foundation no. 2019037022 and 20220205 and Swedish Research Council Grant no. 2019-02409 to KU as main applicant, TL was one of the co-applicants.

## **7.0 Conflicts of interest**

Theresia Hallström is an employee of Nanotemper Technologies GmbH. T Lindahl is the owner of Diapensia AB. APK, AAH, EA, AR, KU and AM declare no conflicts of interest.

## **8.0 Authorship contribution**

AM and TL conceived the study and designed the flow cytometry and MST experiments. AM, TH, APK and AAH performed MST experiments. APK & EA performed flowcytometry experiments. AR and KU designed the SPR experiments, analyzed the data and prepared the figures. AR performed the SPR experiments. AM and TL wrote the manuscript. All authors have read, commented, and approved the final version of the manuscript.

## 9.0 References


1. Chen J, Ishii M, Wang L et al. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. *J Biol Chem* 1994; 269: 16041-16045.
2. Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. *Proc Natl Acad Sci U S A* 1994; 91: 5518-5522.
3. Verhamme IM, Olson ST, Tollefsen DM et al. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. *J Biol Chem* 2002; 277: 6788-6798. DOI: 10.1074/jbc.M110257200
4. Boknas N, Faxalv L, Sanchez Centellas D et al. Thrombin-induced platelet activation via PAR4: pivotal role for exosite II. *Thromb Haemost* 2014; 112: 558-565. DOI: 10.1160/TH13-12-1013
5. Lane DA, Philippou H, Huntington JA. Directing thrombin. *Blood* 2005; 106: 2605-2612. DOI: 10.1182/blood-2005-04-1710
6. Nimjee SM, Oney S, Volovyk Z et al. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. *RNA* 2009; 15: 2105-2111. DOI: 10.1261/rna.1240109
7. Vu TK, Wheaton VI, Hung DT et al. Domains specifying thrombin-receptor interaction. *Nature* 1991; 353: 674-677. DOI: 10.1038/353674a0
8. Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. *Biochem J* 2003; 376: 733-740. DOI: 10.1042/BJ20030954
9. De Candia E, Hall SW, Rutella S et al. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. *J Biol Chem* 2001; 276: 4692-4698. DOI: 10.1074/jbc.M008160200
10. Gandhi PS, Chen Z, Di Cera E. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. *J Biol Chem* 2010; 285: 15393-15398. DOI: M110.115337 [pii]  
10.1074/jbc.M110.115337
11. Lund M, Macwan AS, Tunstromer K et al. Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses. *Front Cardiovasc Med* 2021; 8. DOI: ARTN 717835  
10.3389/fcvm.2021.717835
12. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; 361: 1139-1151. DOI: NEJMoa0905561 [pii]  
10.1056/NEJMoa0905561
13. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. *Clin Pharmacokinet* 2008; 47: 285-295. DOI: 10.2165/00003088-200847050-00001
14. Huel NH, Nar H, Priepke H et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. *J Med Chem* 2002; 45: 1757-1766. DOI: 10.1021/jm0109513
15. Wiene W, Stassen JM, Priepke H et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally

- active prodrug, dabigatran etexilate. *Thromb Haemost* 2007; 98: 155-162. DOI: 07070155 [pii]
16. Yeh CH, Stafford AR, Leslie BA et al. Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. *Plos One* 2016; 11. DOI: ARTN e0157471  
10.1371/journal.pone.0157471
  17. Macwan AS, Boknas N, Ntzouni MP et al. Gradient-dependent inhibition of stimulatory signaling from platelet G protein-coupled receptors. *Haematologica* 2019. DOI: 10.3324/haematol.2018.205815
  18. Boknas N, Faxalv L, Centellas DS et al. Thrombin-induced platelet activation via PAR4: pivotal role for exosite II. *Thrombosis and Haemostasis* 2014; 112: 558-565. DOI: 10.1160/Th13-12-1013
  19. Ramstrom S, Oberg KV, Akerstrom F et al. Platelet PAR1 receptor density- Correlation to platelet activation response and changes in exposure after platelet activation. *Thrombosis Research* 2008; 121: 681-688. DOI: 10.1016/j.thromres.2007.06.010
  20. Li S, Tarlac V, Christanto RBI et al. Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902. *Platelets* 2021; 32: 988-991. DOI: 10.1080/09537104.2020.1810654
  21. Coller BS, Peerschke EI, Scudder LE et al. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. *Blood* 1983; 61: 99-110.
  22. Mazet V. Background correction. 2024.
  23. Breitsprecher D, Schlinck N, Witte D et al. Aptamer Binding Studies Using MicroScale Thermophoresis. *Methods Mol Biol* 2016; 1380: 99-111. DOI: 10.1007/978-1-4939-3197-2\_8
  24. Jerabek-Willemsen M, Wienken CJ, Braun D et al. Molecular interaction studies using microscale thermophoresis. *Assay Drug Dev Technol* 2011; 9: 342-353. DOI: 10.1089/adt.2011.0380
  25. Petoral RM, Herland A, Broo K et al. G-protein interactions with receptor-derived peptides chemisorbed on gold. *Langmuir* 2003; 19: 10304-10309. DOI: 10.1021/la035046v
  26. Wan S, Cui S, Jiang M et al. Dual-target synergistic antithrombotic mechanism of a dabigatran etexilate analogue (HY023016). *Clin Exp Pharmacol Physiol* 2022; 49: 567-576. DOI: 10.1111/1440-1681.13634
  27. Mo M, Kong D, Ji H et al. Reversible Photocontrol of Thrombin Activity by Replacing Loops of Thrombin Binding Aptamer using Azobenzene Derivatives. *Bioconjug Chem* 2019; 30: 231-241. DOI: 10.1021/acs.bioconjchem.8b00848
  28. Tollefsen DM, Feagler JR, Majerus PW. The binding of thrombin to the surface of human platelets. *J Biol Chem* 1974; 249: 2646-2651.
  29. Harmon JT, Jamieson GA. Thrombin binds to a high-affinity approximately 900 000-dalton site on human platelets. *Biochemistry* 1985; 24: 58-64. DOI: 10.1021/bi00322a010
  30. Bakhtiar R. Surface Plasmon Resonance Spectroscopy: A Versatile Technique in a Biochemist's Toolbox. *J Chem Educ* 2013; 90: 203-209. DOI: 10.1021/ed200549g

31. Jerabek-Willemsen M, André T, Wanner R et al. MicroScale Thermophoresis: Interaction analysis and beyond. *J Mol Struct* 2014; 1077: 101-113. DOI: 10.1016/j.molstruc.2014.03.009
32. Schmaier AH, Meloni FJ, Nawarawong W et al. PPACK-thrombin is a noncompetitive inhibitor of alpha-thrombin binding to human platelets. *Thromb Res* 1992; 67: 479-489. DOI: 10.1016/0049-3848(92)90010-8
33. Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol* 2014; 63: 321-328. DOI: 10.1016/j.jacc.2013.07.104
34. Treuheit NA, Beach MA, Komives EA. Thermodynamic compensation upon binding to exosite 1 and the active site of thrombin. *Biochemistry* 2011; 50: 4590-4596. DOI: 10.1021/bi2004069
35. Croy CH, Koeppe JR, Bergqvist S et al. Allosteric changes in solvent accessibility observed in thrombin upon active site occupation. *Biochemistry* 2004; 43: 5246-5255. DOI: 10.1021/bi0499718
36. Dolleman SC, Agten SM, Spronk HMH et al. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity. *J Thromb Haemost* 2022; 20: 996-1007. DOI: 10.1111/jth.15642
37. Chen B, Soto AG, Coronel LJ et al. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. *Mol Pharmacol* 2015; 88: 95-105. DOI: 10.1124/mol.114.096446
38. Yeh CH, Stafford AR, Leslie BA et al. Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. *PLoS One* 2016; 11: e0157471. DOI: 10.1371/journal.pone.0157471
39. Wang X, Zhang Y, Yang Y et al. Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies. *Scientific Reports* 2017; 7: 44040. DOI: 10.1038/srep44040
40. Huntington JA. Molecular recognition mechanisms of thrombin. *J Thromb Haemost* 2005; 3: 1861-1872. DOI: 10.1111/j.1538-7836.2005.01363.x
41. Lee-Rivera I, Lopez E, Lopez-Colome AM. Diversification of PAR signaling through receptor crosstalk. *Cell Mol Biol Lett* 2022; 27: 77. DOI: 10.1186/s11658-022-00382-0
42. Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. *Cell Signal* 2004; 16: 175-186. DOI: 10.1016/s0898-6568(03)00128-1
43. Lechtenberg BC, Freund SM, Huntington JA. Gplbalpha interacts exclusively with exosite II of thrombin. *J Mol Biol* 2014; 426: 881-893. DOI: 10.1016/j.jmb.2013.11.027
44. Arachiche A, Mumaw MM, de la Fuente M et al. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by alpha-thrombin. *J Biol Chem* 2013; 288: 32553-32562. DOI: 10.1074/jbc.M113.472373
45. de la Fuente M, Noble DN, Verma S et al. Mapping the human protease activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. *J Biol Chem* 2012. DOI: M112.341438 [pii] 10.1074/jbc.M112.341438


46. Leger AJ, Jacques SL, Badar J et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. *Circulation* 2006; 113: 1244-1254. DOI: CIRCULATIONAHA.105.587758 [pii] 10.1161/CIRCULATIONAHA.105.587758
47. Smith TH, Li JG, Dores MR et al. Protease-activated receptor-4 and purinergic receptor P2Y<sub>12</sub> dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of beta-arrestin. *J Biol Chem* 2017; 292: 13867-13878. DOI: 10.1074/jbc.M117.782359
48. Bode W, Greyling HJ, Huber R et al. The refined 2.0 Å X-ray crystal structure of the complex formed between bovine beta-trypsin and CMTI-I, a trypsin inhibitor from squash seeds (*Cucurbita maxima*). Topological similarity of the squash seed inhibitors with the carboxypeptidase A inhibitor from potatoes. *FEBS Lett* 1989; 242: 285-292. DOI: 10.1016/0014-5793(89)80486-7
49. Stubbs MT, Laber B, Bode W et al. The refined 2.4 Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. *EMBO J* 1990; 9: 1939-1947.
50. Rezaie AR, Yang L. Deletion of the 60-loop provides new insights into the substrate and inhibitor specificity of thrombin. *Thromb Haemost* 2005; 93: 1047-1054. DOI: 10.1160/TH04-11-0730
51. Jansson M, Sjalander S, Sjogren V et al. Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation. *Thromb Res* 2020; 185: 135-141. DOI: 10.1016/j.thromres.2019.11.010

## Figures




### Figure 1: Important structural components of human alpha thrombin

Human alpha thrombin bound to dabigatran in the active site pocket has been shown. The secondary structural components of thrombin are represented as cartoons and dabigatran as sticks. The structural units of thrombin like exosite 1 (red), exosite 2 (blue), active site (orange) and the 60 loop (green) considered important for binding, catalytic activity, and substrate specificity are shown as spheres.




**Figure 2: Inhibition of thrombin binding to platelets and effects on platelet activation by flow cytometry**

Thrombin binding to platelets and its effect on platelet activation has been shown in the presence and absence of various inhibitors of the thrombin exosite and the active site. Platelet activation markers p-selectin exposure and fibrinogen binding were measured to confirm inhibitors efficacy and platelet reactivity. Negative control test without thrombin has been compared and shown here as control. Median fluorescence intensity of thrombin without any inhibitor has been considered as 100% and the relative fluorescence intensity (%) to thrombin without any inhibitor has been shown as bar graph. The data was calculated using a one-way ANOVA test and results shown are the mean with SEM where number of blood donors,  $n \geq 5$ .




### Figure 3: Inhibition of thrombin binding to platelets as measured by MST

Binding of thrombin to the platelets and the effect of inhibitors were evaluated using MST. In this normalized display, the change in normalized fluorescence ( $\Delta F_{norm}$ ) of thrombin was plotted against the concentration (conc) of the thrombin receptors on platelets in log scale. Binding curve of thrombin to platelets without any inhibitors (control) is compared to the binding of thrombin (55 nM) to platelets in the presence of (A) thrombin exosite specific inhibitors HD1 (1  $\mu$ M) or HD22 (1  $\mu$ M) or both and (B) thrombin active site inhibitors dabigatran (318 nM), argatroban (318 nM) or PPACK (55 nM). The data was calculated using the one phase decay equation in the exponential model using GraphPad Prism, the results shown are mean with SD represented as shadow outlines around the binding curves where, number of blood donors,  $n \geq 5$ .




#### Figure 4: Effect of dabigatran on thrombin binding to exosite ligands by MST

The effect of dabigatran on exosite ligands binding to thrombin without platelets was analyzed by MST. Binding of NHS labeled thrombin (55 nM) to exosite 1 ligand HD1 (A; highest concentration 1  $\mu$ M), exosite 2 ligand HD22 (B; highest concentration 1  $\mu$ M), or another exosite 2 ligand heparin (C; highest concentration 1 U/mL) in the presence (+) or absence (-) of dabigatran (318 nM) was measured by MST. In this normalized display, the change in normalized fluorescence (fraction bound) is plotted against the concentration of the ligand in log scale. All the results shown are mean with SD where  $n \geq 3$ .



**Figure 5: SPR sensogram of thrombin injected onto a SPR chip with a carboxylated dextran with immobilized aptamers**

The interactions between thrombin exosites and DNA aptamers were analyzed. The aptamers HD1 and HD22 are immobilized in separate flow channels to an increase in RU of 971 and 1395, respectively. Thrombin was injected at a concentration of 100 nM in the presence and absence of 300 nM dabigatran. (A) and (B) are sensograms of thrombin in the presence and absence of dabigatran injected over immobilized HD1 and HD22, respectively. To further evaluate the interaction between thrombin and HD22 the injection volume was doubled to 60  $\mu$ L (C). Overall, no significant differences between thrombin in the presence and absence of dabigatran can be observed. Although response curves are of different shapes for the two aptamers, the addition of dabigatran does not alter the response.



### Figure 6: IC<sub>50</sub> of dabigatran for thrombin binding to platelets by flowcytometry

The inhibition potential of dabigatran for thrombin binding to platelets and platelet activation was assessed using flowcytometry. Increasing concentration of the dabigatran (2-600 nM) as log transformation of concentrations to base 10 is plotted against the median fluorescence intensity (MFI) of thrombin binding, p-selectin exposure, or fibrinogen binding and IC<sub>50</sub> values were calculated as described in the methods. The results shown are the mean with SEM where number of blood donors,  $n \geq 5$ .